tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2022 Oct 13;1-22.
doi: 10.1080/22221751.2022.2136535. Online ahead of print.
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-center retrospective cohort
Ensi Ma[SUP] 1 [/SUP], Jingwen Ai[SUP] 2 3 [/SUP], Yi Zhang[SUP] 2 3 [/SUP], Jianming Zheng[SUP] 2 3 [/SUP], Xiaogang Gao[SUP] 4 [/SUP], Junming Xu[SUP] 5 [/SUP], Hao Yin[SUP] 6 [/SUP], Zhiren Fu[SUP] 7 [/SUP], Hao Xing[SUP] 1 [/SUP], Li Li[SUP] 1 [/SUP], Liying Sun[SUP] 8 9 [/SUP], Heyu Huang[SUP] 10 [/SUP], Quanbao Zhang[SUP] 1 [/SUP], Linlin Xu[SUP] 1 [/SUP], Yanting Jin[SUP] 1 [/SUP], Rui Chen[SUP] 4 [/SUP], Guoyue Lv[SUP] 10 [/SUP], Zhijun Zhu[SUP] 8 9 [/SUP], Wenhong Zhang[SUP] 2 3 [/SUP], Zhengxin Wang[SUP] 1 [/SUP]
Affiliations
Abstract
Background & aims: A wave of Omicron infections rapidly emerged in China in 2022, but large-scale data concerning the safety profile of vaccines and Coronavirus disease 2019 (COVID-19) infection features in liver transplant (LT) recipients have not been collected. Therefore, the aim of this study was to assess the protectiveness and safety profile of the inactivated vaccines in LT patients against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infections.
Methods: A multi-center retrospective study was conducted in a cohort with a history of liver transplantation. Electronic questionnaires were used to collect data on demographics, vaccination information, history of liver transplantation, and characteristics of COVID-19 infection until June 2022. The vaccine information included number of doses, vaccine type, injection time, and adverse events.
Results: A total of 1881 participants (487 vaccinated and 1394 unvaccinated patients) were enrolled from seven centers in China. Fourteen of the participants were infected by Omicron, and 50% patients had over 14 days of viral shedding duration. The protection rate of COVID-19 vaccinations to Omicron was 2.59%. The three breakthrough infections occurred more than 6 months after fully vaccinated. A total of 96 (19.7%) vaccinated patients had adverse events, including fatigue, myalgia, liver dysfunction, swelling, and scleroma. There were more Grade 3 adverse events in the preoperative vaccination group than those in the postoperative vaccination group.
Conclusion: Inactivated whole-virion SARS-CoV-2 vaccines are safe in patients with post-liver transplantation. The efficacy of inactivated vaccines decreases after 6 months of vaccination, it is recommended that liver transplant patients get boosted vaccinations as early as possible even when they are fully vaccinated. Although clinical manifestations of Omicron infections were mild in LT patients, unvaccinated patients might have a higher risk of liver dysfunction during infections.
Keywords: Adverse events; Inactivated vaccine; Liver transplantation; Omicron; SARS-CoV-2; protection rate.
. 2022 Oct 13;1-22.
doi: 10.1080/22221751.2022.2136535. Online ahead of print.
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-center retrospective cohort
Ensi Ma[SUP] 1 [/SUP], Jingwen Ai[SUP] 2 3 [/SUP], Yi Zhang[SUP] 2 3 [/SUP], Jianming Zheng[SUP] 2 3 [/SUP], Xiaogang Gao[SUP] 4 [/SUP], Junming Xu[SUP] 5 [/SUP], Hao Yin[SUP] 6 [/SUP], Zhiren Fu[SUP] 7 [/SUP], Hao Xing[SUP] 1 [/SUP], Li Li[SUP] 1 [/SUP], Liying Sun[SUP] 8 9 [/SUP], Heyu Huang[SUP] 10 [/SUP], Quanbao Zhang[SUP] 1 [/SUP], Linlin Xu[SUP] 1 [/SUP], Yanting Jin[SUP] 1 [/SUP], Rui Chen[SUP] 4 [/SUP], Guoyue Lv[SUP] 10 [/SUP], Zhijun Zhu[SUP] 8 9 [/SUP], Wenhong Zhang[SUP] 2 3 [/SUP], Zhengxin Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 36227753
- DOI: 10.1080/22221751.2022.2136535
Abstract
Background & aims: A wave of Omicron infections rapidly emerged in China in 2022, but large-scale data concerning the safety profile of vaccines and Coronavirus disease 2019 (COVID-19) infection features in liver transplant (LT) recipients have not been collected. Therefore, the aim of this study was to assess the protectiveness and safety profile of the inactivated vaccines in LT patients against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infections.
Methods: A multi-center retrospective study was conducted in a cohort with a history of liver transplantation. Electronic questionnaires were used to collect data on demographics, vaccination information, history of liver transplantation, and characteristics of COVID-19 infection until June 2022. The vaccine information included number of doses, vaccine type, injection time, and adverse events.
Results: A total of 1881 participants (487 vaccinated and 1394 unvaccinated patients) were enrolled from seven centers in China. Fourteen of the participants were infected by Omicron, and 50% patients had over 14 days of viral shedding duration. The protection rate of COVID-19 vaccinations to Omicron was 2.59%. The three breakthrough infections occurred more than 6 months after fully vaccinated. A total of 96 (19.7%) vaccinated patients had adverse events, including fatigue, myalgia, liver dysfunction, swelling, and scleroma. There were more Grade 3 adverse events in the preoperative vaccination group than those in the postoperative vaccination group.
Conclusion: Inactivated whole-virion SARS-CoV-2 vaccines are safe in patients with post-liver transplantation. The efficacy of inactivated vaccines decreases after 6 months of vaccination, it is recommended that liver transplant patients get boosted vaccinations as early as possible even when they are fully vaccinated. Although clinical manifestations of Omicron infections were mild in LT patients, unvaccinated patients might have a higher risk of liver dysfunction during infections.
Keywords: Adverse events; Inactivated vaccine; Liver transplantation; Omicron; SARS-CoV-2; protection rate.